HomeMarket NewsThe Insider Scoop: Breaking Down Recent Stock Acquisitions in the Penny Stocks...

The Insider Scoop: Breaking Down Recent Stock Acquisitions in the Penny Stocks Market

Actionable Trade Ideas

always free


Insider Trades: A Glimpse Into Penny Stocks

The Dow Jones index showed a slight dip of around 0.1% on Wednesday. Insider transactions, whether shares are bought or sold, offer valuable insights into the confidence or apprehensions surrounding a company’s future. For those dabbling in penny stocks, such actions could play a key role in shaping investment decisions.

Let’s delve into a few recent noteworthy insider moves in the penny stocks world. For more such updates, dive into Benzinga’s insider transactions platform.

Aldeyra Therapeutics: A Medicinal Affair

  • The Deal: In a bold move, 10% owner Joseph Edelman bet big on Aldeyra Therapeutics, Inc. (ALDX), purchasing a substantial 504,272 shares at an average cost of $3.84, making a total investment of approximately $1.93 million.
  • The Buzz: On April 3, Oppenheimer bumped up Aldeyra’s rating from Perform to Outperform, setting a target price of $10.
  • The Rx: Aldeyra Therapeutics focuses on crafting next-gen medicines to enhance the lives of individuals grappling with immune-related diseases.

Retractable Technologies: Needling the Market

  • The Move: Thomas J Shaw, President, and CEO of Retractable Technologies, Inc. (RVP), acquired 8,292 shares at an average price of $1.15, spending roughly $9,499 in the process.
  • Current Scenario: On March 29, Retractable Technologies unveiled its 2023 results.
  • The Specialization: Retractable Technologies deals in the design, creation, and marketing of safety syringes and other medical safety tools for healthcare professionals.

Check Out the Scene: Keep an eye on Levi Strauss, Conagra Brands, and 3 other stocks as Thursday approaches.

Alzamend Neuro: A Mindful Investment

  • The Play: Milton C Ault III, a Director at Alzamend Neuro, Inc. (ALZN), snagged 334 shares at an average price of $0.91, totaling around $304.
  • What’s Unfolding: On December 11, 2023, Alzamend Neuro got the green light with a β€œStudy May Proceed” approval from the FDA for the launch of study AL001-PTSD01, a Phase 2A exploration of AL001 for post-traumatic stress disorder (PTSD).
  • The Focus: Alzamend Neuro is a budding biopharmaceutical company aimed at revolutionizing products for treating neurodegenerative diseases and mental health disorders like Alzheimer’s.


Hungry for more market insights? Don’t miss our primer on pre-market activity here.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.